REG - Sareum Holdings PLC - Result of AGM

Sareum HoldingsAnnouncement

16/12/2021 16:25

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211216:nRSP9446Va&default-theme=true

RNS Number : 9446V  Sareum Holdings PLC  16 December 2021

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Results of AGM

Cambridge, UK, 16 December 2021 - Sareum Holdings plc (AIM: SAR), the
specialist drug development company delivering targeted small molecule
therapeutics to improve the treatment of cancer and autoimmune diseases, held
its Annual General Meeting ("AGM") today and all resolutions were duly passed.
Details of the proxy voting are shown in the table below.

 Ordinary resolutions                                                           Votes For     %     Votes Against  %    Votes Total  % of ISC Voted  Votes Withheld

 1. Receive and adopt Report of the Directors and financial statements for the  139,633,376   99.8  240,000        0.2  139,873,376  4.1             314,311
 year
 2. Receive and adopt Renumeration Committee report for the year                139,046,887   99.4  724,500        0.5  139,771,387  4.1             416,300
 3. Re-elect Clive Birch as Director of the Company                             138, 886,944  99.3  825,424        0.6  139,712,368  4.1             475,319
 4. Re-elect Michael Owen as a Director of the Company                          138,886,944   99.3  825,424        0.6  139,712,368  4.1             475,319
 5. Appoint Shipleys LLP as auditor                                             139,141,640   99.5  320,015        0.3  139,461,655  4.1             726,032
 6. Directors' authority to allot new shares                                    134,116,471   95.9  1,414,362      1.0  135,530,833  4.0             4,656,854
 Special Resolution
 7. Directors' authority to allot equity securities for cash                    138,495,068   99.0  1,326,587      0.9  139,821,655  4.1             366,032

ISC - Issued Share Capital

The full text of each of the resolutions is set out in the Notice of AGM,
available in the Investors section of the Company's website
(www.sareum.com/investors (http://www.sareum.com/investors/document-centre/) )

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO                          01223 497 700

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)
 James Steel                                020 7418 8900

 Hybridan LLP (Nominated Broker)

 Claire Noyce                               020 3764 2341

 MEDiSTRAVA Consulting (Financial PR)

 Mark Swallow/ David Dible                  020 3928 6901

 

About Sareum

Sareum is a specialist drug development company delivering targeted small
molecule therapeutics to improve the treatment of cancer and autoimmune
diseases. The Company aims to generate value through licensing its candidates
to international pharmaceutical and biotechnology companies at the preclinical
or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine
kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical
development as therapies for autoimmune diseases, including the 'cytokine
storm' immune system overreaction to Covid-19 and other viral infections,
(SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral,
selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell
replication and DNA damage repair mechanisms. Preliminary Phase 2 and
comprehensive preclinical data suggest SRA737 may have broad application in
combination with other oncology and immune-oncology drugs in genetically
defined patients.

SRA737 was discovered and initially developed by scientists at The Institute
of Cancer Research in collaboration with Sareum, and with funding from Sareum
and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to
Sierra Oncology Inc. Sierra continues to explore options that would enable the
development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange,
trading under the ticker SAR. For further information, please visit the
Company's website at www.sareum.com (http://www.sareum.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGDKABBABDDKBD